Gerber Kawasaki Wealth & Investment Management Geron Corp Transaction History

Gerber Kawasaki Wealth & Investment Management

$2.28 Billion
Q4 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$1.27 - $1.54 $19,050 - $23,100	-15,000 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$1.15 - $1.59 $5,750 - $7,950	5,000 Added 50.0%	15,000 $19,000
Q4 2018 Feb 08, 2019	SELL	$0.98 - $1.85 $490 - $925	-500 Reduced 4.76%	10,000 $10,000
Q3 2018 Nov 06, 2018	BUY	$1.76 - $6.38 $880 - $3,190	500 Added 5.0%	10,500 $16,000
Q1 2018 May 08, 2018	BUY	$1.81 - $5.98 $18,100 - $59,800	10,000 New	10,000 $42,000
Q4 2017 Feb 06, 2018	SELL	$1.8 - $2.32 $18,000 - $23,200	-10,000 Closed	0 $0
Q3 2017 Nov 13, 2017	SELL	$1.99 - $2.65 $7,960 - $10,600	-4,000 Reduced 28.57%	10,000 $22,000
Q2 2017 Aug 09, 2017	BUY	N/A	14,000	14,000 $39,000

Others Institutions Holding GERN

# of Institutions

306

Shares Held

465M

Call Options Held

1.07M

Put Options Held

648K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $608M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gerber Kawasaki Wealth & Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Gerber Kawasaki Wealth & Investment Management with notifications on news.

Account